T‐025 strongly suppressed growth of the allograft tumors (Fig 7A) without inducing body weight losses (Fig 7B), suggesting that CLK inhibitors could exert anti‐tumor effects against MYC‐driven breast cancers. Here, CLK1 is linked to breast cancer.